Surgical management of liver metastases from colorectal cancer

Journal of Oncology Practice

Volumn 12, Issue 1, 2016, Pages 33-39

  Dhir, Mashaal ^a   Sasson, Aaron R ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISAPPEARING LIVER METASTASIS; FATTY LIVER; HEPATOGRAPHY; HUMAN; LIVER INJURY; LIVER RESECTION; LIVER SURGERY; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL VEIN EMBOLIZATION; PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COLORECTAL NEOPLASMS; DISEASE MANAGEMENT; LIVER NEOPLASMS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; LIVER NEOPLASMS; MORBIDITY; MORTALITY; TREATMENT OUTCOME;

EID: 84958542968     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2015.009407     Document Type: Review

References (49)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
2. Manfredi S, Lepage C, Hatem C, et al: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244:254-259, 2006
3. Siegel R, Desantis C, Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104-117, 2014
4. Mi K, Kalady MF, Quintini C, et al: Integrating systemic and surgical approaches to treating metastatic colorectal cancer. Surg Oncol Clin N Am 24:199-214, 2015
5. Heinemann V, von Weikersthal LF, Decker T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 15: 1065-1075, 2014
6. Schwartzberg LS, Rivera F, Karthaus M, et al: PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240-2247, 2014
7. Venook AP, Niedzwiecki D, Lenz H-J, et al: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32, 2014 (suppl 5; abstr LBA3)
8. van Kessel CS, Buckens CF, van den Bosch MA, et al: Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: A meta-analysis. Ann Surg Oncol 19:2805-2813, 2012
9. Moulton CA, Gu CS, Law CH, et al: Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: A randomized clinical trial. JAMA 311:1863-1869, 2014
10. Ekberg H, Tranberg KG, Andersson R, et al: Determinants of survival in liver resection for colorectal secondaries. Br J Surg 73:727-731, 1986
11. Spolverato G, Ejaz A, Azad N, et al: Surgery for colorectal liver metastases: The evolution of determining prognosis. World J Gastrointest Oncol 5:207-221, 2013
12. Tzeng CW, Aloia TA: Colorectal liver metastases. J Gastrointest Surg 17: 195-201, 2013; quiz 201-202.
13. Strasberg SM: Nomenclature of hepatic anatomy and resections: A review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 12:351-355, 2005
14. Abdalla EK, Denys A, Chevalier P, et al: Total and segmental liver volume variations: Implications for liver surgery. Surgery 135:404-410, 2004
15. Ribero D, Chun YS, Vauthey JN: Standardized liver volumetry for portal vein embolization. Semin Intervent Radiol 25:104-109, 2008
16. van Lienden KP, van den Esschert JW, de Graaf W, et al: Portal vein embolization before liver resection: A systematic review. Cardiovasc Intervent Radiol 36:25-34, 2013
17. Shindoh J, D Tzeng CW, Vauthey JN: Portal vein embolization for hepatocellular carcinoma. Liver Cancer 1:159-167, 2012
18. Dhir M, Lyden ER, Wang A, et al: Influence of margins on overall survival after hepatic resection for colorectal metastasis: A meta-analysis. Ann Surg 254:234-242, 2011
19. Pawlik TM, Scoggins CR, Zorzi D, et al: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-722, 2005; discussion 722-724 2005
20. Sadot E, Groot Koerkamp B, Leal JN, et al: Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: Surgical technique or biologic surrogate? Ann Surg 262:476-485, 2015; discussion 483-485 2005
21. Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 371:1007-1016, 2008
22. Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Longterm results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208-1215, 2013
23. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
24. Peeters M, Price TJ, Cervantes A, et al: Final results from a randomized phase 3 study of FOLFIRI 1/- panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 25:107-116, 2014
25. Masi G, Loupakis F, Pollina L, et al: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249:420-425, 2009
26. Adam R, Wicherts DA, de Haas RJ, et al: Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J Clin Oncol 27:1829-1835, 2009
27. Wong R, Cunningham D, Barbachano Y, et al: A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22: 2042-2048, 2011
28. Uetake H, Yasuno M, Ishiguro M, et al: A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808). Ann Surg Oncol 22:908-915, 2015
29. Folprecht G, Gruenberger T, Bechstein W, et al: Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 25: 1018-1025, 2014
30. Alberts SR, Horvath WL, Sternfeld WC, et al: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 23: 9243-9249, 2005
31. Brouquet A, Abdalla EK, Kopetz S, et al: High survival rate after two-stage resection of advanced colorectal liver metastases: Response-based selection and complete resection define outcome. J Clin Oncol 29:1083-1090, 2011
32. Lam VW, Laurence JM, Johnston E, et al: A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford) 15:483-491, 2013
33. Kishi Y, Zorzi D, Contreras CM, et al: Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17:2870-2876, 2010
34. Schwarz RE, Berlin JD, Lenz HJ, et al: Systemic cytotoxic and biological therapies of colorectal liver metastases: Expert consensus statement. HPB (Oxford) 15: 106-115, 2013
35. Pawlik TM, Schulick RD, Choti MA: Expanding criteria for resectability of colorectal liver metastases. Oncologist 13:51-64, 2008
36. Wolf PS, Park JO, Bao F, et al: Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: A single institution experience. J Am Coll Surg 216:41-49, 2013
37. Vauthey JN, Pawlik TM, Ribero D, et al: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072, 2006
38. Auer RC, White RR, Kemeny NE, et al: Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 116:1502-1509, 2010
39. Benoist S, Brouquet A, Penna C, et al: Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 24:3939-3945, 2006
40. Elias D, Goere D, Boige V, et al: Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: Impact of adjuvant intraarterial hepatic oxaliplatin. Ann Surg Oncol 14:3188-3194, 2007
41. van Vledder MG, de Jong MC, Pawlik TM, et al: Disappearing colorectal liver metastases after chemotherapy: Should we be concerned? J Gastrointest Surg 14: 1691-1700, 2010
42. Rubbia-Brandt L, Giostra E, Brezault C, et al: Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18:299-304, 2007
43. Abbas S, Lam V, Hollands M: Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol 2011:763245, 2011
44. Hamady ZZ, Lodge JP, Welsh FK, et al: One-millimeter cancer-free margin is curative for colorectal liver metastases: A propensity score case-match approach. Ann Surg 259:543-548, 2014
45. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, 1999; discussion 318-321
46. Gomez D, Cameron IC: Prognostic scores for colorectal liver metastasis: Clinically important or an academic exercise? HPB (Oxford) 12:227-238, 2010
47. Schirripa M, Bergamo F, Cremolini C, et al: BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 112:1921-1928, 2015
48. Brudvik KW, Kopetz SE, Li L, et al: Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102:1175-1183, 2015
49. Asiyanbola B, Chang D, Gleisner AL, et al: Operative mortality after hepatic resection: Are literature-based rates broadly applicable? J Gastrointest Surg 12: 842-851, 2008